目的 分析冠心丹參滴丸與替格瑞洛聯(lián)合療法在冠心病心絞痛方面的臨床效果。方法 選取2023年1月—2024年6月淮南東方醫(yī)院集團(tuán)總醫(yī)院收治的106例冠心病心絞痛患者病例資料進(jìn)行回顧性分析，按治療方法分成兩組（各53例）。對(duì)照組口服替格瑞洛片，90 mg/次，2次/d。治療組在對(duì)照組治療基礎(chǔ)上舌下含服冠心丹參滴丸，10粒/次，3次/d。觀察兩組患者臨床療效（心絞痛、心電圖療效），比較治療前后兩組患者心絞痛發(fā)作情況，心絞痛視覺(jué)模擬量表（VAS）、Duke和心絞痛生活質(zhì)量問(wèn)卷（APQLQ）評(píng)分，及血清細(xì)胞因子中性粒細(xì)胞與淋巴細(xì)胞比值（NLR）、紅細(xì)胞壓積（RDW）、血小板壓積（PCT）和血小板分布密度（PDW）水平。結(jié)果 心絞痛療效、心電圖療效的總有效率：治療組（94.34%、88.68%）都高于對(duì)照組（81.13%、73.58%）（P＜0.05）。硝酸甘油用量、心絞痛發(fā)作持續(xù)時(shí)間和發(fā)作次數(shù)：治療組都少于對(duì)照組（P＜0.05）。治療后，兩組心絞痛VAS、APQLQ評(píng)分及NLR、RDW、PCT、PDW水平均低于同組治療前（P＜0.05），且治療組變化幅度更甚（P＜0.05）。治療后，兩組Duke評(píng)分顯著增加（P＜0.05），且治療組變化幅度更甚（P＜0.05）。結(jié)論 冠心丹參滴丸聯(lián)合替格瑞洛治療冠心病心絞痛能有效抑制患者機(jī)體炎癥反應(yīng)，減少血栓形成，從而能進(jìn)一步控制心絞痛發(fā)作、減輕疼痛，改善預(yù)后，促進(jìn)患者生活質(zhì)量改善。

Objective To analyze the clinical effect of Guanxin Danshen dropping pills combined with ticagrelor in the treatment of angina pectoris of coronary heart disease. Methods The clinical data of patients (106 cases) with angina pectoris in coronary heart disease in General Hospital of Huainan Oriental Hospital Group from January 2023 to June 2024 were analyzed retrospectively. According to the treatment method, they were divided into two groups (53 cases in each group). Patients in the control group were po administered with Ticagrelor Tablets, 90 mg/time, twice daily. Patients in the treatment group were sublingually administered with Guanxin Danshen Dripping Pills on the basis of the control group, 10 pills/time, three times daily. Patients in two groups were treated for 4 weeks. The clinical efficacy (angina pectoris, electrocardiogram) of the two groups were observed., and the angina attacks, VAS, Duke, and APQLQ scores for angina pectoris, and the levels of NLR, RDW, PCT, and PDW were compared between the two groups before and after treatment. Results The total effective rates of angina pectoris and electrocardiogram in the treatment group (94.34%, 88.68%)were higher than those in the control group (81.13%, 73.58%). The dosage of nitroglycerin, duration and frequency of angina pectoris attack in the treatment group were less than those in the control group (P < 0.05). After treatment, the angina VAS, APQLQ scores, NLR, RDW, PCT, and PDW levels in two groups were lower than those before treatment in the same group (P < 0.05), and the changes were more significant in the treatment group (P < 0.05). After treatment, a significant increase in the Duke score was observed in both groups (P < 0.05), and the changes were more significant in the treatment group (P < 0.05). Conclusion The combination treatment of coronary heart disease angina pectoris with Guanxin Danshen Dripping Pills and ticagrelor can effectively inhibit the patient's inflammatory response, reduce thrombus formation, further control angina attacks, alleviate pain, improve prognosis, and promote the improvement of the patient's quality of life.

R972

安徽省衛(wèi)生健康委科研項(xiàng)目（AHWJ2021a037）